Aspen Pharmacare unaudited interim financial results
Aspen Pharmacare Holdings Limited naudited interim financial results for the six months ended 31 December 2018, a mixed view with both some positives and negatives resulting in a major sell off this morning”
Shares in Aspen Pharmacare Limited (Aspen) plunged as much as 44% down to R78.00 per share after the pharmaceutical company’s interim results disappointed the market. This is down from a close of R140.33 the previous day. The group released its results this morning and the bears have entered the market with massive force. This is the biggest decrease in the share price for Aspen since 1998. The share has been in and out of volatility auction throughout the trading day. The share price has recovered back to around the R100.00 level as of 12:35 pm.
The group reported that revenues grew 1% to R19.7 billion with normalized headline earnings falling 9% to R3.6 billion. Borrowings increased by R6.7 billion to R53.5 billion, leaving the company highly geared and exposed to more financial risk. This has undoubtably worried investors as the share price continues to plunge.
- Aspens slumps to low of R68.81 after earnings release
- Marginal recovery with share price trading at R99.00 as at 12:30 am
- Proceeds from disposal of Nutritionals business delayed
- De-leveraging the balance sheet a high priority
Financial Highlights – Six months ended 31 December 2018
- Revenue up 1% to R19 673 million (2017: R19 509 million)
- Gross profit up 2% to R10 236 million (2017: R10 049 million)
- EBITDA down 3% to R5 534 million (2017: R5 711 million)
- Operating profit down 6% to R4 420 million (2017: R4 701 million)
- Headline earnings down 19% to R2 937 million (2017: R3 645 million)
- Profit for the period from continuing operations down 16% to R2 871 million
- Normalised HEPS down 9% (6% in constant currency) to 743 cents (2017: 814 cents)
- Operating cash flow per share of 317 cents representing 47% rate of conversion of operating profit.
The consensus analyst ratings from Bloomberg comprise of 5 buys, 5 holds and 1 sell as of 8 March 2019. The 12-month target price consensus is R186.24, compared with a reference price of R86.00, this represents a potential return of 116.6% should the stock be bought at the reference price. The last 12 month return on the stock has been -66.5% at the abovementioned reference price.
Comparison with Adcock Ingram – Full Year Period
*All amounts in ZAR
Sterile Focus Brands
Revenue remained constant with the prior period at R7.8 billion with gross profit improving to R4.3 billion. The higher gross profit margin was as a result of the lower Thrombosis manufacturing costs. The Sterile Focus Brands comprise of the Anesthetics and Thrombosis portfolios.
This segment has struggled with ongoing supply constraints affecting all of its major operating regions, except Japan. Revenue was 1% lower at R4.4 billion, but this is a solid result given the supply issues faced. China and Latin American were up 6% and 22% respectively, driving growth in the segment. In Japan, the benefit of strong volume gains were offset by price decreases throughout the period. The groups opinion is that supply should improve by 2020 and be unconstrained from thereon out.
Revenue remains unchanged at R3.4 billion compared with the prior period. Emerging markets outperformed developed markets with former up 7%, driven by strong growth in China.
Revenue remained unchanged at R11.9 billion, comprising of Regional Brands and Manufacturing.
Regional brands comprise 45% of the groups revenue and grew at revenues at 3% over the period. Revenue growth was hampered by poor performance by the oncology portfolio in Europe which diluted margins. Growth was realized in all other territories.
Manufacturing was hit hard by the tough trading and economic environment. Revenues declined 10% to R3 billion coupled with lower volumes over the period. The group also lost a major tender and had to suspend the sale of heparin to third parties which contributed to the decline in growth, with resultant lower volumes squeezing margins further.
Funding and Balance Sheet Concerns
Borrowings increased by R6.7 billion to R53.5 billion over the period, with the increase comprising of R4.9 million of acquisition payments, CAPEX of R1.5 billion and R1 billion as a result of Rand weakness. Operating cash flow per share of 317 cents represents a 47% rate of conversion of operating profit. Net interest paid is covered 5 times by EBITDA.
De-leveraging the balance sheet remains a key priority for Aspen. Long term debt is sitting at R46.73 billion contributing to a debt to equity ratio of 116.83%. The result is that Aspen is highly geared and therefore exposed to much more financial risk. In turn, shareholders would require a much higher return on investment to warrant the high financial risk. It is therefore critical for future investment that Aspen de-leverage their balance sheet, in order to attract future shareholder investment.
The group has already taken steps to accelerate the de-leveraging process. The pending receipt from the disposal of the Nutritionals business is estimated to result in inflows of around EUR 635 million. In addition, the divestment of the non-core pharmaceutical portfolio in the Asia Pacific region will result in further inflows. CEO Steven Saad has stated that this is one of his major priorities for the group going forward and we can expect further divestments to come.
Research compiled by Tyron Searle, IG Trading services.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Live prices on most popular markets